21 May 2013
Keywords: roche, mabthera, approved, eu, hoffmann-la, says, received
Article | 04 June 1998
Hoffmann-La Roche says that it has received approval from the EuropeanCommission to market its anti-CD20 monoclonal antibody MabThera
(rituximab) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 June 1998
3 June 1998
20 May 2013
© 2013 thepharmaletter.com